TICKERNERD
Menu
HAEHAEHealthcare · Medical Devices

HAE Stock Forecast: Haemonetics Corp. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$87
+1.46% on the day

The 11 Wall Street analysts covering Haemonetics Corp. hold a median 12-month price target of $90 — +3.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$3.9B
Ticker Nerd rank
94 / 100
Median analyst target
$90
Analysts covering
11
Total return, dividends reinvested
1W
+8.6%
1M
+15.6%
YTD
+8.3%
1Y
+16.1%
From 52W high
−0.4%
From 52W low
+82.1%
$48
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HAE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Haemonetics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
93
Issuance
92
Value
90
Accruals
88
Quality
84
Momentum
68
Revisions
60
Growth
47
Size
27

Volatility (93): The share price has been relatively steady.

Growth (47): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Haemonetics Corp. — and when they’d sell — is the membership.

Wall Street

HAE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HAE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$60$70$80$90$100$110Oct 25Jan 26Apr 26Jul 26HAEHigh $104Median $90Low $62

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
8 Buy3 Hold0 Sell
Low $62Median $90High $104

The green dot is the last close — the median target sits +3.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 July 2026MizuhoMaintainsOutperform—
15 July 2026MizuhoMaintainsOutperform$85 → $90
26 June 2026BTIGReiteratesBuy$84
26 June 2026BTIGReiteratesBuy—
17 June 2026BTIGReiteratesBuy—
15 June 2026MizuhoMaintainsOutperform—
28 May 2026CitigroupMaintainsNeutral—
22 May 2026B of A SecuritiesUpgradeBuy—
12 May 2026Barrington ResearchMaintainsOutperform—
8 May 2026JP MorganMaintainsNeutral—
13 Apr 2026MizuhoMaintainsOutperform—
7 Apr 2026CitigroupMaintainsNeutral—
11 Mar 2026CitigroupMaintainsNeutral—
6 Feb 2026Barrington ResearchMaintainsOutperform—
6 Feb 2026BTIGReiteratesBuy—
6 Feb 2026CitigroupMaintainsNeutral—
6 Feb 2026MizuhoMaintainsOutperform—
2 Feb 2026Barrington ResearchMaintainsOutperform—
12 Jan 2026Barrington ResearchMaintainsOutperform—
9 Jan 2026BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

HAE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.4%
Analysts raising
0
Analysts cutting
1
Fundamentals

Haemonetics Corp. (HAE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
42.4×

Cheaper than 18% of US stocks

Price / sales
3.0×

Cheaper than 42% of US stocks

Price / book
4.9×

Cheaper than 21% of US stocks

EV / EBITDA
13.8×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
4.8%

Higher than 41% of US stocks

Earnings growth (YoY)
4.8%

Higher than 43% of US stocks

Gross margin
57.2%

Higher than 72% of US stocks

Operating margin
13.9%

Higher than 72% of US stocks

Net margin
7.3%

Higher than 65% of US stocks

Returns & dividend
Return on equity
12.0%

Higher than 69% of US stocks

Return on assets
6.5%

Higher than 84% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HAE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
HAEHaemonetics Corp.$3.9B
94
ITGRInteger Holdings Corp.$4.2B
74
IRTCiRhythm Holdings, Inc.$3.8B
82
LIVNLivaNova PLC$4.4B
99
ESTAEstablishment Labs Holdings, Inc.$2.7B
78
NEOGNeogen Corp.$2.6B
94
TMDXTransMedics Group, Inc.$2.6B
34
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HAE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest HAE news & analysis

New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths

PRNewsWire · 3 Aug 2026positive

Haemonetics announced the publication of a retrospective cohort study providing new evidence on the safety and efficacy of its VASCADE MVP XL venous vascular closure system in large-bore sheath electrophysiology procedures. The study reportedly represents the largest cohort using the system to date.

Why it matters — The study adds published clinical evidence supporting the VASCADE MVP XL vascular closure system, a relevant product in Haemonetics' medical technology portfolio.

Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline

Zacks Investment Research · 30 July 2026negative

Zacks Investment Research previewed Haemonetics' upcoming Q1 earnings report, stating the company's earnings are expected to decline and that it lacks the key ingredients for a likely earnings beat.

Why it matters — The preview suggests Haemonetics may face a challenging earnings report, which could affect investor expectations for the company's near-term financial performance.

Martin Madaus Elected to Haemonetics Board of Directors

PRNewsWire · 28 July 2026positive

Haemonetics Corporation announced that Martin Madaus has been elected to its Board of Directors, effective July 24, 2026. Dr. Madaus brings more than 30 years of leadership experience in the diagnostics and life sciences tools industries.

Why it matters — Adding a seasoned executive with deep experience in diagnostics and life sciences tools to the board could bring valuable strategic perspective to Haemonetics.

FAQ

Frequently asked questions about HAE stock

What is the HAE stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Haemonetics Corp. have a median 12-month price target of $90, with estimates ranging from $62 to $104. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HAE stock a buy right now?

Of the 11 analysts covering Haemonetics Corp., 8 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Haemonetics Corp. 94 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HAE?

As at 1 Aug 2026, Haemonetics Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).

Will HAE stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +3.1% from the last close, and Ticker Nerd's factor model ranks Haemonetics Corp. 94 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HAE stock forecast for 2030?

No analyst covering Haemonetics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HAE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $62 to $104 over the next 12 months.

How has HAE stock performed over the past year?

Haemonetics Corp. returned +16.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Haemonetics Corp. do?

Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions for organizations around the world. The company plays a crucial role in the healthcare industry by offering devices and services that aim to improve the quality, efficiency, and safety of blood supply.

What is the latest news on HAE?

The most recent item we track (PRNewsWire, 3 Aug 2026): "New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths". Haemonetics announced the publication of a retrospective cohort study providing new evidence on the safety and efficacy of its VASCADE MVP XL venous vascular closure system in large-bore sheath electrophysiology procedures. The study reportedly represents the largest cohort using the system to date.

Company

About Haemonetics Corp.

Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions for organizations around the world. The company plays a crucial role in the healthcare industry by offering devices and services that aim to improve the quality, efficiency, and safety of blood supply. Haemonetics is known for its comprehensive portfolio, which includes blood collection and processing systems, plasma collection devices, and software solutions for blood centers and hospitals. The core focus of Haemonetics' offerings lies in enhancing blood donor and patient care, optimizing blood banks' operations, and ensuring the safety and availability of blood and blood components. It serves a wide array of sectors, including hospitals, blood centers, and plasma collection centers, facilitating the global demand for transfusion medicine. With its headquarters in Boston, Massachusetts, Haemonetics continues to influence the landscape of healthcare through its commitment to innovation and its significant contributions to enhancing blood management practices. By catering to a vital segment of the healthcare system, Haemonetics Corporation supports the delivery of essential medical treatments and therapies worldwide.

CEO Mr. Christopher A. Simon · 3,009 employees · United States · https://www.haemonetics.com